SCHEMBL5034802

SCHEMBL5034802

CCCn1c(=O)c2[nH]c(Cc3cncnc3)nc2n(CCc2cc(NC(C)=O)ccc2O)c1=O

nearest known ligand 0.52

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 8/20 0.52
PCK1 P35558 4/20 0.51
RXFP1 Q9HBX9 1/20 0.49
PDE5A O76074 1/20 0.45
ADORA1 P30542 3/20 0.44
ADORA2A P29274 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5034809 0.87 ADORA2B (0.51) ADORA2BPCK1RXFP1ADORA1ADORA2A
SCHEMBL5031641 0.84 ADORA2B (0.50) ADORA2BPCK1RXFP1ADORA1ADORA2A
SCHEMBL5028591 0.78 PCK1 (0.66) ADORA2BPCK1RXFP1ADORA1ADORA2A
SCHEMBL1334411 0.77 ADORA1 (0.42) ADORA2BRXFP1ADORA1ADORA2A
SCHEMBL5033076 0.76 ADORA2B (0.57) ADORA2BPCK1RXFP1ADORA1ADORA2A
SCHEMBL5035051 0.73 PCK1 (0.73) ADORA2BPCK1RXFP1ADORA1ADORA2A
SCHEMBL3981235 0.73 PCK1 (0.83) ADORA2BPCK1RXFP1PDE5AADORA2A
SCHEMBL4420554 0.73 PCK1 (0.58) ADORA2BPCK1ADORA1ADORA2A
SCHEMBL3985137 0.72 PCK1 (0.91) ADORA2BPCK1RXFP1
SCHEMBL5030792 0.72 PCK1 (0.69) ADORA2BPCK1RXFP1ADORA1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293705-A1 A1 ADENOSINE RECEPTOR ANTAGONISTS ENDACEA, INC. (US) 2008-11-27 US disclosed
US-7423041-B2 e.g. 3-[2-(4-Aminophenyl)ethyl]-8-benzyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility ENDACEA, INC. (US) 2008-09-09 US disclosed
US-20070161629-A1 A1 Adenosine Receptor Antagonists ENDACEA, INC. (US) 2007-07-12 US disclosed
US-7202252-B2 A1 adenosine receptor antagonists ENDACEA, INC. (US) 2007-04-10 US disclosed
US-20050119258-A1 A1 adenosine receptor antagonists ENDACEA, INC. 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119258-A1 A1 adenosine receptor antagonists ADORA1, ADORA2A, ADORA3 ADORA2B 4/4885PCK1 3496/4885RXFP1 205/4885
US-20070161629-A1 A1 Adenosine Receptor Antagonists ADORA1, ADORA2A, ADORA3 ADORA2B 4/4885PCK1 3496/4885RXFP1 205/4885
US-20080293705-A1 A1 ADENOSINE RECEPTOR ANTAGONISTS ADORA1, ADORA2A, ADORA3 ADORA2B 4/4885PCK1 3496/4885RXFP1 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.